ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024

|   Science & Medicine

  • Interim data from Phase I/II EVICTION study shows favorable safety profile and promising efficacy for ICT01 in combination with pembrolizumab in refractory melanoma patients

ImCheck Therapeutics announced today that updated data from its ongoing Phase I/II study EVICTION will be presented in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago. The poster will provide new data from the study assessing ICT01, a humanized anti-BTN3A monoclonal antibody that selectively activates γ9δ2 T cells, in combination with checkpoint inhibitor (CPI) pembrolizumab. The results, specifically in patients with CPI-refractory melanoma, support the therapeutic potential of the ICT01‒pembrolizumab combination.

Our objective with the EVICTION study is to validate ICT01’s promise as an innovative therapy and inform the next steps of its clinical development. The data presented at ASCO further define ICT01’s therapeutic potential, in particularin combination with pembrolizumab, where we see promising data in CPI-refractory patients. ImCheck intends to further investigate this combination regimen in refractory solid tumors, where patients have limited treatment options,” commented Pierre d’Epenoux, Chief Executive Officer of ImCheck Therapeutics.

Data from EVICTION presented at ASCO will include full safety data from all cohorts and preliminary efficacy data from ongoing assessments performed every 8 weeks in patients with metastatic melanoma. ICT01‒pembrolizumab combination treatment showed a clinically manageable safety profile with generally mild and clinically manageable first-dose Grade 1/2 infusion-related reactions (38%) and cytokine release syndrome (19%) as the most common adverse events across all doses and indications. In the CPI-refractory melanoma group, 21 patients were evaluable at week 16 with 3 partial responses and a disease control rate of 42%. In addition, biomarker analyses revealed clinical response was associated with baseline BTN3A tumoral expression, sustained elevation of IFNɣ levels, and tumor microenvironment remodeling. Based on these findings, biomarker-driven patient selection will be further investigated as a potential enrichment strategy.


Details of the poster presentation are:

  • Abstract title: “EVICTION study: ICT01, an anti-Butyrophilin 3A monoclonal antibody activating γ9δ2 T cells in combination with pembrolizumab in checkpoint inhibitor refractory melanoma.”
  • Session title: Melanoma/Skin Cancers
  • Abstract number: 9534
  • Poster board: 318
  • Presenter: Dr Stephane Champiat, Gustave Roussy
  • Authors: Stephane Champiat, Martin Wermke, Cecile Vicier, Johann S. De Bono, Emiliano Calvo, Jorge Ramón, Evan Thomas Hall, Elena Garralda, Vladimir Galvao, Emanuela Romano, Antoine Italiano, Esma Saada, Benoit You, Aude De Gassart, Maelle Mairesse, Emmanuel Valentin, Patrick Brune, Daniel Olive, Katrien Lemmens, Paul Frohna
  • Date/Time: Saturday June 1st, 2024, 1:30–4:30 pm CST
  • Location:   Hall A - McCormick Place

The ASCO poster will be available on ImCheck’s corporate website after the presentation has been completed.